KRAS and pancreatic neoplasm: Deletion of Nrf2 in a pancreatic cancer mouse model with mutant KRAS and p53 (KPC model) decreased formation of precancerous lesions and the development of pancreatic cancer, while increasing sensitivity to oxidative stress and chemotherapeutic agents [188].